T1	Participants 101 150	patients with advanced or recurrent breast cancer
T2	Participants 317 366	patients with advanced or recurrent breast cancer
T3	Participants 950 978	221 patients were assessable
T4	Participants 1775 1818	patients who had not received prior therapy
